Wilkinson Global Asset Management LLC Sells 510 Shares of Johnson & Johnson (NYSE:JNJ)

Wilkinson Global Asset Management LLC decreased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 3.2% in the 4th quarter, Holdings Channel reports. The fund owned 15,641 shares of the company’s stock after selling 510 shares during the quarter. Wilkinson Global Asset Management LLC’s holdings in Johnson & Johnson were worth $2,262,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in JNJ. Convergence Investment Partners LLC boosted its stake in Johnson & Johnson by 13.3% in the 4th quarter. Convergence Investment Partners LLC now owns 16,191 shares of the company’s stock worth $2,342,000 after purchasing an additional 1,897 shares during the period. Allied Investment Advisors LLC lifted its holdings in shares of Johnson & Johnson by 1.3% in the fourth quarter. Allied Investment Advisors LLC now owns 62,464 shares of the company’s stock valued at $9,034,000 after purchasing an additional 799 shares in the last quarter. Northcape Wealth Management LLC boosted its position in shares of Johnson & Johnson by 11.9% during the fourth quarter. Northcape Wealth Management LLC now owns 26,486 shares of the company’s stock worth $3,830,000 after buying an additional 2,813 shares during the period. Atlas Legacy Advisors LLC bought a new position in shares of Johnson & Johnson during the fourth quarter worth about $251,000. Finally, Bank of Jackson Hole Trust acquired a new stake in Johnson & Johnson in the 4th quarter valued at approximately $1,176,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Johnson & Johnson

In related news, EVP Timothy Schmid sold 403 shares of the firm’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares in the company, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Mark A. Weinberger acquired 1,000 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The shares were purchased at an average cost of $147.22 per share, with a total value of $147,220.00. Following the transaction, the director now directly owns 1,000 shares of the company’s stock, valued at $147,220. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $162.35 on Friday. The firm’s fifty day moving average price is $148.93 and its two-hundred day moving average price is $155.90. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The company has a market cap of $390.87 billion, a P/E ratio of 24.41, a P/E/G ratio of 2.53 and a beta of 0.52. Johnson & Johnson has a one year low of $140.68 and a one year high of $168.85.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.05. The firm had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business’s revenue was up 5.3% on a year-over-year basis. During the same period in the prior year, the firm earned $2.29 EPS. Equities analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be given a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.06%. Johnson & Johnson’s payout ratio is presently 74.59%.

Analyst Ratings Changes

Several equities analysts have recently weighed in on JNJ shares. Wolfe Research started coverage on shares of Johnson & Johnson in a research note on Friday, November 15th. They set an “outperform” rating and a $190.00 price target for the company. Wells Fargo & Company decreased their target price on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a research report on Thursday, January 23rd. Guggenheim boosted their price target on shares of Johnson & Johnson from $162.00 to $166.00 and gave the stock a “neutral” rating in a research report on Monday, February 3rd. Argus upgraded Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. Finally, Morgan Stanley reduced their price target on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a research report on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $170.67.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.